Recombinant Salmonella typhimurium has been used as an oral vaccine for various microbial pathogens. Here 
The major way that microbial pathogens cause disease is by colonization of, or invasion through, mucosal surfaces. Therefore the induction of immune responses to a pathogen at these surfaces should serve as a first line of defense against infection. Immunoglobulin A (IgA) is the predominant isotype of antibody in mucosal secretions (34) . The oral administration of antigen has been shown to result in IgA antibody responses in a variety of secretions (e.g., saliva) via stimulation of the common mucosal immune system (32, 33) . When antigen is given orally, it is taken up by the specialized M cells interspersed throughout the luminal epithelium of Peyer's patches in the gut-associated lymphoid tissue (GALT) and delivered to the underlying lymphoid cells. The antigen-stimulated T and B cells leave Peyer's patches, migrate to numerous mucosal tissues, and mediate an antigen-specific IgA immune response in the external secretions (27) .
Since most orally administered nonviable antigens are inefficient in stimulating the GALT, several approaches are currently being investigated to develop oral vaccines which are more effective in inducing mucosal IgA responses. Inert particulate carriers such as microspheres and liposomes, in addition to live delivery systems such as bacterial and viral carriers, are being studied for use as oral vaccines (32) . Recombinant Salmonella strains are particularly useful as oral vaccines since Salmonella organisms colonize Peyer's patches in the GALT (4) . Several types of attenuated Salmonella strains have been developed for use as oral vaccine delivery systems, including those with mutations in aromatic biosynthetic metabolism (aroA and aroC mutants), UDP-galactose synthesis (galE mutants), phosphate metabolism (phoP mutants), and regulation of outer membrane proteins (ompR mutants) (reviewed by Curtiss [5] and Doggett [10] ). Ideally, Salmonella vaccine strains should have two attenuating mutations to prevent reversion to the virulent phenotype. For example, Salmonella typhimurium Acya Acrp mutants, which lack adenylate cyclase and the cyclic AMP receptor protein, have been shown to be stable and safe for in vivo use (6) (7) (8) . Oral immunization with these mutants has been shown to induce humoral and cellular responses to Salmonella strains (44) and to cloned gene products expressed by this live vector (3) .
Streptococcus mutans (serotype c) and Streptococcus sobrinus (serotype g) are considered major etiologic agents of human dental caries (31) . The pathogenesis of this disease involves at least two initial stages: a sucrose-independent stage, in which the bacteria adhere to glycoproteins in the pellicle coating the tooth surface, followed by a sucrose-dependent stage involving adherence and colonization of mutans streptococci (15, 20) . Finally, acid production by the colonizing S. mutans and S. sobrinus results in demineralization of the tooth surface. A virulence factor believed to be involved in adherence of S. mutans is Ag I/II (28, 39) . This protein functions as a receptor for salivary agglutinin or as an adhesin which interacts with the saliva-coated tooth surface (1, 19) . S. sobrinus produces a protein called SpaA, which is very similar to Ag I/II. Within the middle region of the two proteins, SpaA and Ag I/II share 66% amino acid identity (29, 46) .
Previous studies have tested the effectiveness of Ag I/II in inducing protective antibody responses against S. mutans infection (39) . Subcutaneous immunization of Rhesus monkeys with Ag I/II in incomplete Freund's adjuvant resulted in IgG antibodies to Ag I/II in serum as well as in gingival crevicular fluid, and the presence of these antibodies correlated with protection from caries formation (30) . Oral administration of Ag I/II does not result in notable immune responses. However, salivary IgA responses were induced when Ag I/IT was given in liposomes (35) or when Ag I/II was coupled to the B subunit of cholera toxin and given along with a small amount of cholera toxin as adjuvant (9, 35, 41) . The induction of salivary IgA and anti-Ag I/IT responses in rats correlated with protection against S. mutans-induced dental caries (35) . In other studies it has been shown that intranasal immunization of mice (47) 13 ,000 x g at 4°C), aliquoted, and stored at -70°C until used.
Restriction endonuclease mapping. Plasmid DNA was isolated from S. typhimurium X4072(pYA2905) (42) The amount of SpaA in the whole-cell lysate was determined by interpolation from the standard curve generated from known concentrations of purified native SpaA by using a four-parameter logistic algorithm (Softmax; Molecular Devices Corp.). Total protein in the whole-cell lysate was determined by using the Micro BCA protein assay kit (Pierce) .
Plasmid construction. The plasmid used in these studies, pYA2905, was obtained from Roy Curtiss III, Washington University, St. Louis, Mo. pYA2905 contains three tandem repeats of a 0.48-kb fragment encoding the major SpaA immunodominant determinant fused to the 1.2-kb fragment encoding a minor SpaA immunodominant determinant (18) (Fig. 1) . In addition to encoding antigenic determinants of SpaA, pYA2905 contains the S. typhimurium gene asd, which encodes 3-semialdehyde dehydrogenase (14) . This enzyme is required for the synthesis of DAP, an essential component of the peptidoglycan in the cell wall of gram-negative organisms. 37°C with aeration for 4 h. The bacteria were centrifuged for 10 min at 3,000 x g and resuspended in PBS. The number of bacteria in the suspension was determined by reading the optical density at 660 nm. The bacteria were then diluted to 4 x 109 CFU/ml in intubation medium (26) Mediatech, Washington, D.C.). The bacterial inoculum was then diluted in sterile PBS and plated on bismuth sulfite agar (Difco). After incubation at 37°C for 18 h, the colonies on the plates were enumerated and used to determine the actual immunizing dose ofS. typhimurium x4072(pYA2905). Groups of rats were immunized on day 0, on days 0 and 7, or on days 0, 7, and 21. Serum, saliva, and fecal samples were collected at weekly intervals (two rats per time point) and assayed by ELISA for antibody activity to S. sobrinus 6715 and S. typhimurium LT-2. Following collection of gut secretions, saliva, and serum, the rats were sacrificed. The spleen and all Peyer's patches from each rat were removed and assessed for the number of recoverable S. typhimurium X4072(pYA2905) cells.
Sample collection. Gut secretions were collected and processed as described previously (12) . Briefly, rats were given a high-salt lavage solution at 15-min intervals for 1 h prior to being anesthetized with a solution of ketamine and xylazine as described above. They were then given pilocarpine (Sigma; 1 ml of a 75-mg/ml solution per 100 g of body weight). Gut secretion was collected into a petri dish and then centrifuged for 13 ,000 x g for 10 min at 4°C. Saliva was collected with a Pasteur pipette and also centrifuged for 13,000 x g for 10 min at 4°C. The clarified gut secretion and saliva were stored at -70°C until assayed for antibody activity. Blood was collected by cardiac puncture while the rats were under anesthesia. The blood was allowed to clot at 4°C, and, after centrifugation at 2,700 x g, the serum was collected and stored at -70°C until assayed for antibody activity by ELISA, as described below.
In vivo recovery of S. typhimurium X4072(pYA2905). To determine the persistence of the recombinant S. typhimurium X4072(pYA2905) in rats, we sacrificed the animals at approximately weekly intervals. The spleens and Peyer's patches from immunized animals were removed and placed in sterile PBS (5 ml). Single-cell suspensions were prepared by processing the tissues through a 22-gauge wire mesh. The resulting cell suspensions were then diluted, and aliquots were spread on bismuth sulfite agar. After incubation at 37°C for 24 h, CFU were counted. The data are expressed as the number of CFU per tissue per rat.
Salmonella colonies were isolated from Peyer's patches of individual animals for analysis of SpaA expression. The isolates were grown overnight at 37°C in L broth, and whole-cell lysates were prepared as described by Sambrook et al. (42) . Each culture (1 ml) was centrifuged for 30 s at 14,000 rpm in an Eppendorf microcentrifuge (12,000 x g). The pellet was resuspended in 0.5 ml of ice-cold 50 mM Tris-HCl (pH 7.4). [EU] ) was established by using a pool of rat anti-S. sobrinus or anti-S. typhimurium hyperimmune sera or bile from immunized animals for an anti-S. sobrinus or anti-S. typhimunium serum Ig or mucosal IgA standard. The antibody activity in the standard pool was assigned a level of antibody activity in EU per milliliter, whereby 1 EU per milliliter equaled the dilution of the standard giving an optical density reading of 0.1. The level of antibody activity (in EU per milliliter) in serum, saliva, and gut secretion samples run simultaneously with the standard was determined by interpolation from the standard curve by using a four-parameter logistic algorithm (Softmax; Molecular Devices Corp.). In some experiments the levels of salivary and gut secretion IgA antibody are expressed as the optical densities at 405 nm for samples diluted 1:5.
RESULTS
Characterization of pYA2905 and its product in recombinant S. typhimurium. pYA2905 is a 6.2-kb plasmid (11); upon digestion with EcoRI, 4.6-and 1.6-kb fragments were generated (Fig. 1) . Digestion with BglII yielded three fragments, of 3.3, 1.7, and 1.3 kb, as expected from the restriction endonuclease map. The recombinant SpaA encoded by pYA2905 was expressed in the cytoplasm of the recombinant bacterium, although a trace amount was seen in the periplasmic fraction (Fig. 2) . The molecular mass of the recombinant SpaA is approximately 145 kDa, compared with the 210-kDa native SpaA protein (Fig. 2) (11) , which is very similar to the 185-kDa Ag I/II (40) . Salmonella cells detected in Peyer's patches of animals continued to decrease after the second immunization on day 7 (Fig.  6 ). On day 21 following the initial immunization, recombinant Salmonella cells were recovered from only one of the two rats analyzed. No Salmonella cells were detected in Peyer's patches of immunized rats on day 25, 35, or 49. A third immunization on day 21 did not lead to an increase in the number of recoverable Salmonella cells in Peyer's patches of immunized animals. Salmonella cells were recovered from Peyer's patches on day 25 but not on day 35 or 49. In addition, Salmonella cells were not detected in spleens of immunized animals 7 days after the initial immunization (data not shown). SpaA was expressed by the Salmonella cells isolated from the rats, as determined by immunoblot analysis (data not shown).
Anti-Streptococcus and anti-Salmonella antibodies were detected in the serum of animals receiving multiple (two or three) immunizations (Fig. 7) . The level of anti-Streptococcus activity in serum increased following the first and second immunizations and peaked on day 21 (Fig. 7A) . After the third immunization, a slight increase in antibody activity was seen on day 42, which was similar to the level seen on day 21 . The serum response in rats given multiple immunizations (Fig. 7) persisted longer than in rats given a single immunization (Fig. 4) .
The anti-Salmonella activity in serum in animals given three immunizations peaked on day 36 and then, following a slight decrease, began to increase again on day 51 (Fig. 7B) . Unlike the anti-Streptococcus responses in serum, the level of antiSalmonella activity in serum was augmented in animals receiving three immunizations compared with those receiving two immunizations.
The level of salivary IgA anti-Streptococcus antibody activity in animals given multiple immunizations increased during the first week (Fig. 8A) . Following a gradual decrease after the second immunization, an increase in activity was seen after day 21. The level of anti-Streptococcus activity seen on day 25 in rats immunized on days 0, 7, and 21 was higher than that observed in rats given two immunizations. The salivary antiSalmonella activity was also higher in rats given booster doses than in rats given two immunizations (Fig. 8B) . Animals given either two or three immunizations had peak salivary antiSalmonella IgA antibody responses on day 25.
Fecal IgA anti-Streptococcus and anti-Salmonella responses were also detected (Fig. 9) . Following two immunizations, the level of anti-Streptococcus activity decreased and then increased on days 25 and 36 (Fig. 9A) . This was different from that seen in animals receiving three immunizations, in which the anti-Streptococcus response peaked on day 25 and then gradually declined (Fig. 9A) . The level of anti-Salmonella antibody activity peaked on day 25 in rats given multiple immunizations (Fig. 9B) . In addition, the anti-Salmonella response in animals receiving three immunizations was more sustained than in those receiving two immunizations (Fig. 9B) .
DISCUSSION
In our studies with Fischer rats, the Acya Acrp S. typhimurium mutant X4072(pYA2905) persisted in the GALT, with peak numbers of recombinant Salmonella cells detected within the first 7 days in the Peyer's patches of orally immunized rats. This supports data from previous studies showing that Acya Acrp Salmonella mutants, even though they are avirulent, are capable of invading the GALT and inducing immunity in orally immunized BALB/c mice (6, 8) . Similarly, in previous work with BALB/c mice, Acya Acrp Salmonella cells persisted in the GALT, as well as in the spleens, with numbers of recoverable plasmid pYA2905 (Fig. 1) , as well as the high-level expression of the recombinant SpaA protein (Fig. 2) 
